Cazenove Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Cazenove Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$624K	Buy	+2,667	New	+$525K	0.5%	39

Other funds holding CLDX

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SCA

SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Cazenove Capital Management's CLDX Position: Q2 2013 in Review

Cazenove Capital Management opened a new position in Celldex Therapeutics (CLDX) in Q2 2013: 2,667 shares worth $624K. The stake represents 0.5% of the portfolio and ranks #39 among its holdings.

129 funds tracked by Wall St. Rank hold CLDX as of Q2 2013.

Cazenove Capital Management held 2,667 shares of Celldex Therapeutics worth $624K as of Q2 2013.
Celldex Therapeutics was a new Cazenove Capital Management position in Q2 2013.
Celldex Therapeutics made up 0.5% of Cazenove Capital Management's portfolio in Q2 2013, its #39 holding.
129 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2013.

Based on Cazenove Capital Management's 13F filing for Q2 2013, filed 14 Aug 2013.